Drug recall · January 12, 2022
Cefixime 400 mg capsule recall
Why: Failed Impurities/Degradation Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefixime 400 mg capsule, packaged in a) 2-count bottle (NDC 70518-2749-02), b) 2-count blister pack (NDC 70518-2749-03), Rx only, MFG: Ascend Labs, LLC, Montvale, NJ 07645
- Lots / codes
Lot #: a) B1429436-110821, Exp 07/2022; B1429434-110821, Exp 11/2022; B1429435-110821, Exp 11/2022; B1279449-072021, Exp 07/2022; B1279457-072021, Exp 07/2022; B1279442-072021,Exp 07/2022; B1057718-012621, Exp 01/2022; B1057727-012621, Exp 01/2022; b) B1358139-092121, Exp 03/2022; B1424654-110421, B1437578-111421, Exp 05/2022
- Quantity
- a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules
- Company
- RemedyRepack Inc., Indiana, PA
- Distribution
- Product was distributed to two direct accounts in MI and PA.
- Initiated
- December 29, 2021 · Voluntary: Firm initiated
- Classified
- January 5, 2022
- Reported
- January 12, 2022
- Ended
- April 14, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefixime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.